PRM16 Evaluation of Personalized Breast Cancer Test-Treatment Strategies - A Cross-Validation Study Between a Discrete-Event Simulation and a Markov Model  by Jahn, B. et al.
1Kantar Health, New York, NY, USA, 2National Institute of Public Health, Saitama, Japan,
3Kantar Health, Princeton, NJ, USA
OBJECTIVES: Large, nationally-representative data sources of epidemiological and
health outcome information are scarce in Japan. The aim of this study was to
assess the evidence for validity of a national patient-reported survey of the adult
Japanese population comparedwith existing population-based studies.METHODS:
The data source for this comparison was the 2010 Japan National Health andWell-
ness Survey (NHWS) (N25,000). The NHWS is a self-reported, Internet-based sur-
vey administered to the adult population of Japan. A random stratified sampling
framework was implemented, with age and gender strata, to ensure the final
NHWS sample was identical to the demographic composition of the Japanese pop-
ulation. Sampling weights were applied to all analyses to project to the entire
country’s population. Prevalence statistics generated from NHWS were then com-
pared with existing epidemiological information obtained through literature
reviews. RESULTS: For certain conditions defined by clinical measures that pa-
tients may not be aware of (e.g. COPD), large differences in prevalence between
NHWS (COPD  1.37%) and the literature (10.9% reported airflow limitations in
Fukuchi et al., 2004) were observed. In these cases, differences generally disap-
peared when analyses focused purely on prevalence of awareness of diagnosis
(NHWS 1.37% vs. Fukuchi et al., 2004: 1.02%). Though some differences were ob-
served, most other conditions were generally similar between NHWS and the lit-
erature (e.g., atrial fibrillation: 0.73% vs. 0.56%, respectively; asthma: 2.55% vs.
3.40%, respectively). CONCLUSIONS: Although population-level data in Japan are
scarce, patient-reported data can provide useful epidemiological estimates as well
as valuable health outcome data across a variety of conditions. In many instances,
NHWS prevalence rates were comparable to other sources though, because the
NHWS is purely self-report, it provides a perspective based on awareness of diag-
nosis, whichmay not be relevant for all disease. Further comparisons between the
NHWS and other population-based studies are warranted.
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OBJECTIVES: National statistics on the epidemiology and health outcomes associ-
ated with various conditions are difficult to obtain in China. The aim of this study
was to assess the evidence for validity of a patient-reported survey compared with
existing epidemiological data on prominent chronic conditions. METHODS: The
data source for this comparison was the 2010 China National Health andWellness
Survey (NHWS) (N19,954). The NHWS is a self-reported survey administered to
the adult population of urban China using a mixed methodology (an Internet sur-
vey and computer assisted web interviews). A random stratified sampling frame-
work was implemented to ensure the final NHWS sample was identical to the
demographic composition of the urban China population. Horvitz-Thompson sam-
plingweights were applied to all analyses to project to the entire urban population.
Existing epidemiological information was obtained through literature reviews.
RESULTS: A prior systematic review of rheumatoid arthritis across China esti-
mated the pooled prevalence across 41 studies at 0.37%. The NHWS estimated the
prevalence in urban China at 2.14%. A population-based study conducted in 2001-2
using objective clinical measures (fasting blood glucose test and oral glucose tol-
erance test), estimated the prevalence of type 2 diabetes (T2D) at 6.1%, with 2.1%
having been diagnosed. The NHWS estimated the diagnosed prevalence of T2D at
2.95%. Other conditions were generally similar between NHWS and the literature.
CONCLUSIONS: These results suggest that a self-reported patient survey can pro-
vide useful information about the urban Chinese population. The reliance on self-
report underestimates conditions defined by clinical measures that the patient
may not be aware of (e.g., diabetes, COPD) and may result in measurement error
due tomedical illiteracy (rheumatoid arthritis versus osteoarthritis) but has shown
consistency with other population studies that analyzed awareness of the condi-
tion. Further comparisons between the NHWS and other population studies are
warranted.
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OBJECTIVES: Created in 2002, the Patient-Reported Outcome and Quality of Life
Instruments database (PROQOLID) provides a detailed description of 713 generic or
disease-specific assessment tools on the Internet (www.proqolid.org). The objec-
tive of this study is to identify the PRO instruments available for use in Taiwan.
METHODS: The PROQOLID database was explored using the search engine and
selecting in the field language the key words “Chinese for Taiwan.” RESULTS: For-
ty-four questionnaireswere identified representing 6.17% of the instruments avail-
able in PROQOLID. Out of these 44 questionnaires, six were generic (e.g., Duke
Health Profile, Euroqol EQ-5D, Psychosocial Impact of Assistive Device Scale, Fer-
rans and Powers Quality of Life Index, SF-12 Health Survey, and SF-36 Health Sur-
vey). Fourteen different therapeutic areas were identified (e.g., endocrine, system
diseases, neoplasms, respiratory tract diseases, nervous system diseases, or psy-
chiatric disorders), representing 33 different indications. Only two questionnaires
were available for pediatric use (i.e., the Pediatric Quality of Life Inventory Diabetes
Module and the Pediatric Quality of Life Inventory CancerModule). Asthmawas the
most frequent indication (four questionnaires available), followed by diabetesmel-
litus (three questionnaires), Benign Prostatic Hyperplasia (BPH) (two question-
naires) erectile dysfunction (two questionnaires) and Pain (two questionnaires).
Within the therapeutic area of neoplasms, four different indications were identi-
fied (breast, cervix, lung, and ovary). Only one instrument was available for use in
Parkinson’s disease (Parkinson’s Disease Questionnaire – PDQ-39), and one for use
in Alzheimer’s disease (Clinical Dementia Rating). Not a single instrument was
identified in therapeutic areas such as bacterial infections, eye diseases, virus dis-
eases (e.g., AIDS) or otorhinolaryngologic diseases (e.g., rhinitis). CONCLUSIONS:
Results of this overview show that PRO instruments available for use in Taiwan
cover awide variety of indications. Some therapeutic areas, however, are either not
very well represented (e.g., pediatrics or nervous diseases) or not at all (e.g., infec-
tious diseases).
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OBJECTIVES: According to the Principles on Drug Reimbursement Price Approval(P-
DRPA) issued by the Bureau of National Health Insurance (BNHI) Taiwan, in the
submission of new drug application to Pharmaceutical Benefit Scheme, MTC anal-
yse of several clinical trials could be used to assess comparative effectiveness of the
new drug to the currently best treatment(s), with or without the studies directly
compared the treatments. Quality of the MTC analysis should be evaluated in a
structured way in order to digest the potentially complex analysis.METHODS:We
identify the critical points that would have impact on the validity and consistency
of the MTC analysis by reviewing the published papers of methodology of indirect
comparison of clinical trials. RESULTS: The following checking points were pro-
posed: 1) Check the analysis aim and quality of systematic review, including: topic
(patient, intervention, comparator, outcome, PICO), systematic searching for com-
pleteness of all relevant studies included, and quality of included studies and
extracted data; 2) Check the analysis method and the included materials, includ-
ing: the framework of comparison; statistical method; identify in each pair of com-
parison the number of trials included; the important characteristics of each pair of
comparison; and meta-analysis result of each comparison pair including the syn-
thesized effect and heterogeneity; and 3) Check the analysis results, including:
reanalyze the data with the proposed model; check the consistency between indi-
rect evidence and direct evidence if available; check the sensitivity by constructing
the comparison framework from simple (limited comparisons) to complex (all
comparisons) or including additional study characteristics; check the results using
different statistical models and different effect measurements (such as risk ratio,
risk difference, odds ratio etc.). CONCLUSIONS:MTC is a relatively new but poten-
tially valuable method to analyze evidence for comparing effectiveness of several
interventions. Experience of using the structural checking points will be built up.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug andmedical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database gathering details of Post-Marketing Requirements (PMRs), i.e., studies
requested by the following regulatory agencies: EuropeanMedicines Agency (EMA,
EU), the Food andDrugAdministration (FDA, USA), and theHaute Autorité de Santé
(HAS, France). METHODS: All drug approvals published by the EMA, the FDA, and
the HAS between January 1, 2005 and December 31, 2011 were reviewed to retrieve
PMRs. The information was categorized as follows: product description (brand
name, INN, indication, etc.), application details, PMR details, and information
source. RESULTS: For the FDA, we reviewed 763 original approvals and 944 supple-
ments and included, respectively, 201 and 110 drugs approved with PMRs. For the
EMA, we reviewed 349 marketing authorizations and included 38 files with PMRs.
For theHAS, 3674 opinionswere publishedwith only 174 opinionswith PMRs.Many
HAS requests were long-term follow-up studies. About 43% of the PMRs requested
by the FDA were pediatric studies. At present, the EMA also requires pediatric
studies but under a Pediatric Investigation Plan (PIP). Since 2005, 21 PIPs have been
requested. Nomatterwhich agency is reviewed, all kinds of indications are covered
by the PMRs, e.g., treatment of sepsis, asthma, malaria, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about PMRs requested in Europe and in the USA. It will be useful to observe the
trends in studies requested, to anticipate the demands, and to integrate the studies
as early as possible in the product development process. The Post-Marketing Re-
quirements database will be available online in an independent website, with ac-
cess by subscription.
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OBJECTIVES: Breast cancer is the most common malignant disease in Western
women. In the ONCOTYROL research center, a decision-analytic Breast Cancer
Outcomes & Policy (BCOP) model is being developed to evaluate the cost-effective-
ness of the new 21-gene assay that supports personalized decisions on adjuvant
chemotherapy. Model validation is essential to build confidence in the model re-
sults and to influence decision makers. Based on the new ISPOR-SMDM best prac-
tice recommendations, the process of model validation will be presented.
METHODS: The 21-gene assay was evaluated by simulating a hypothetical cohort
of 50year old women over a lifetime time horizon, adopting a societal perspective.
Main model outcomes were life-years gained, quality-adjusted life-years (QALYs)
gained and costs. Themajor focus of the presentation is on cross validation, i.e. the
comparison ofmodeling results between the discrete event simulation (DES) BCOP-
model and the Markov model of the THETA (Toronto Health Economics and Tech-
nology Assessment) Collaborative. Therefore, the BCOP-model has been populated
with the Canadian parameters of the THETA-model. RESULTS: Cross validation
started with comparison of model parameters related to the natural history of the
disease (undiscounted life years, number of breast cancer recurrences/deaths).
Thereafter, quality of life and cost outcomes were compared. The comparison
included point estimates of the outcomes of the deterministic analysis of the
Markovmodel aswell as the probabilistic runwith theDES results and combination
(ICERs). The absolute differences of expected life years gained for women after
surgery ranged from -0.35 to 0.43 years depending on the treatment strategy for
specific risk groups. For the probabilistic analysis, confidence intervals as well as
distributions of model outcomes were compared. CONCLUSIONS: Cross model
validation is a suitable approach to identify and correct modeling errors and to
explain remaining differences of modeling results.
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OBJECTIVES: Treatments for Alzheimer’s disease (AD) have currently been proved
for effectiveness but the selection needs to determine whether the clinical benefits
justify their additional costs. This study aimed to evaluate the cost-effectiveness of
donepezil treatment of mind to moderate AD compared with usual care in the
perspective of provider and society. METHODS: A Markov model composed of 4
health states (mild, moderate, severe, and death) was constructed to extrapolate
the results over a 5-year period. The study included costs of donepezil, costs of
comorbidity treatment, and costs of informal care. Effectiveness was measured in
terms of quality-adjusted life year (QALY). Cost and utility data were directly col-
lected from Thai AD population, but transition probabilities and the effect of done-
pezil were derived from literature review. All costs and effects were discounted at
3% per annum. One-way and probabilistic sensitivity analyses were performed.
RESULTS: The results demonstrated that with the threshold level of Thai 1GPD per
capita (approximately 148,000 Baht/QALY in 2011), donepezil was not a cost-effec-
tive treatment for mild or moderate AD for both societal (incremental cost-effec-
tiveness ratio (ICER)  284,473 Baht/QALY) and provider perspectives (ICER 
369,148 Baht/QALY). The resultswere very sensitive to utility value and the effect of
donepezil. Donepezil became more cost-effective than usual care when the will-
ingness to pay level increased to at least 155,000 and 375,000 Baht/QALY for societal
and provider perspectives respectively. CONCLUSIONS:With a limited health care
resources, using donepezil for the treatment of AD might not be cost-effective in
Thai context.
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OBJECTIVES: Chronic kidney disease (CKD) is a common and growing global health
issue characterized by reduced glomerular filtration rate (GFR, mLs/min/1.73m2).
While investigators have used short-term changes in GFR as an endpoint, the re-
lationship between this endpoint and long-term outcomes has not been reported.
The objective herewas to estimate andquantify this relationship in order to predict
the timing and number of cases of end-stage renal disease (ESRD) occurring over
the lifetime of a cohort of hypothetical CKD patients with moderate and advanced
disease.METHODS:We constructed a three-state Markov model (functioning kid-
ney, ESRD, and death) with an annual cycle length to project GFR on long-term
health outcomes. Using published GFR-specific risk equations, and adjusting for
confounders, we estimated the probability of ESRD (assumed at GFR10) and time
to death according to baseline GFR categories defined by the United States (U.S.)
Kidney Disease Outcomes Quality Initiative. Included in the modeling was a term
representing two types of CKD patients characterized by “slow” and “fast”
progression. RESULTS: For CKD patients aged 55 years, projected lifetime proba-
bilities of progressing to ESRD were: 0.05, 0.25, 0.81, and 0.97 in GFR categories
45-59, 30-44, 15-29, and15, respectively. Projectedmean survival timeswere: 16.7,
13.7, 11.4, and 9.4 years for the sameGFR categories. Themodelwas calibratedwith
mortality data reported by the U.S. Renal Data System. CONCLUSIONS: The model
can project the potential impact of baseline GFR on long-term outcomes in CKD.
Estimating the time spent in GFR categories allows quantification of the entire
trajectory of CKDuntil renal failure or death. In future, themodelmay be refined by
incorporating additional empirical data describing longer-term follow-up.
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OBJECTIVES: To demonstrate if a nationally representative panel dataset can be
used to evaluate if quality of life (QoL) impacts are associated with changes in body
mass index (BMI). The aim was to estimate the utility increments (or decrements)
associated with weight loss (or gain) for application in economic evaluations of
obesity interventions. METHODS: Data from the Household, Income and Labour
Dynamics in Australia survey (HILDA) was used in the analysis. HILDA is a house-
hold-based panelwith 17,209 individuals from6,987 households collected annually
since 2001. This survey uses the SF-36 and the transformed SF-6D utility weight to
capture quality of life. Currently, there are 5 waves providing information on BMI.
The panel nature of the data was exploited with econometric techniques to show
the effect of changes in BMI (between different BMI classification groups) on quality
of life. RESULTS: The results demonstrated that being under-weight, over-weight
or obese is associated with reduced quality of life. When adjusting for other ex-
planatory variables, only the association between the obese category and dimin-
ished quality of life remained. The results from the panel data identified that only
those who remain severely obese over time experience significant reductions in
quality of life. Movements between other BMI categories were not associated with
significant impacts on quality of life. CONCLUSIONS: Economicmodels that assess
the cost-effectiveness of obesity interventions using cross-sectional data may
overestimate the QoL gain following a reduction in BMI. This could lead to non-
optimal policy oriented decisions. Population panel datasets may provide a better
estimate. Using econometric techniques alongside traditional cost-effectiveness
models offers a richer avenue of obtaining model inputs and more certainty in
regards to quantifying gains and losses in QoL.
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OBJECTIVES: Hepatitis B virus (HBV) is estimated to infect 350 million people all
over the world. Most infection with HBV do not induce clinical liver disease, while
less than 30% of them develop severe liver disease. We do not know, however, the
approximate number of the annual newly HBV infection and/or HBV development
in Japan. Then, we make Markov model with HBV infection and estimate annual
probability to disease development.METHODS:We reviewed clinical research pa-
per related to HBV infection published in Japan until December 2011. To research
Japanese original data, we used ‘Igaku Chuo Zasshi’ (Japanese medical journals
database), and JapaneseMinistry of Health, Labour andWelfare research database.
We then extracted some parameters (e.g., patients outcome, treatment, time hori-
zon) and calculated annual probability of disease development. RESULTS: We
made HBV infection model and estimate annual probability to disease develop-
ment from 22 eligible Japanese research papers and reports. The HBV Markov
model started from HBs antigen negative, then HBV infection, divided into 2 col-
umns (asymptomatic career, acute hepatitis) and so on. Each columns annual
probability were detected from clinical trial data in Japan. CONCLUSIONS: We
estimated HBV infection and related diseases progress probability by one-year in
Japan.Wewill estimate the cost of each diseases treatment, patient’s quality of life,
and then we will make Japanese HBV Markov model near future.
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OBJECTIVES:A reliable and validmeasure is essential to evaluating and enhancing
patient medication adherence. There is no validated patient-reported medication
adherence measure in Singapore. This study aimed to validate the 8-item Morisky
Medication Adherence Scale (MMAS) in patients taking warfarin in Singapore.
METHODS: A cross-sectional survey was conducted in a convenient sample of 174
patients taking warfarin at an anticoagulation clinic in Singapore in 2011. Socio-
demographics and International Normalized Ratio (INR) valueswere obtained from
patient interview and hospital databases. Respondents completed the MMAS in
English or Chinese depending on their preference. The scale scores ranged from 0
to 8, with higher scores indicating better medication adherence. Reliability was
assessed using Cronbach’s alpha. Criterion-related validity was examined by relat-
ing the MMAS score to warfarin refill rate. Construct validity was examined via
factor analysis and hypothesis testing. RESULTS: The reliability of the MMAS was
moderate (Cronbach’s alpha  0.56). The scale scores were associated with warfa-
rin refill rates (p  0.02). Confirmatory factor analysis showed that the eight items
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